Spots Global Cancer Trial Database for HE4 as a Relapse Biomarker in Ovarian Cancers
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: HE4 as a Relapse Biomarker in Ovarian Cancers
Official Title: Determination of the Interest of HE4 as a Relapse Biomarker in Ovarian Cancers Stages IIIb, IIIc and IV After Neo-adjuvant Chemotherapy and Surgery.
Study ID: NCT02595281
Conditions
Interventions
Study Description
Brief Summary: HE4 is a more sensitive marker than CA-125 in patients with ovarian cancers. The interest of serum HE4 before surgery has been demonstrated to predict overall survival and its interest has also been shown in combination with CA-125 (ROMA algorithm) to identify high risk patients. To date, no study shows clearly the predictive potential of serum HE4 as an early relapse biomarker in ovarian cancers.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
Locations
BENGRINE-LEVEVRE Leïla, Dijon, Centre Georges François Leclerc, France
DEMARCHI Martin, Strasbourg, Centre Paul Strauss, France
LONGO Raphaelle, Metz, CHU Metz Thionville, France
KURTZ Jean-Emmanuel, Strasbourg, Hôpital Civil, France
KALBACHER Elsa, Besançon, Hôpital Jean Minjoz, France
GAVOILLE Céline, Vandœuvre-lès-Nancy, Institut De Cancérologie De Lorraine, France
SAVOYE Aude-Marie, Reims, Institut Jean Godinot, France
Contact Details
Name: Céline Gavoille, MD
Affiliation: Institut de Cancérologie de Lorraine
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
